骨髓增生异常综合征治疗现状  

Current therapy of the patients with myelodysplastic syndrome

作　　者：赵文舒 戴敏[1] ZHAO Wen-shu;DAI Min(Department of Hematology,Nanfang Hospital,Southern Medical University,Guangdong Guangzhou 510515,China)

机构地区：[1]南方医科大学南方医院血液内科,广东广州510515

出　　处：《内科急危重症杂志》2022年第2期89-94,共6页Journal of Critical Care In Internal Medicine

基　　金：国家自然科学基金(No:81500149)。

摘　　要：骨髓增生异常综合征(MDS)的异质性决定了治疗的复杂性和个体化。目前,异基因造血干细胞移植仍然是唯一能够根治MDS的选择,但部分患者因各种原因无法接受移植治疗,主要根据国际预后评分系统(IPSS-R)评分指导MDS患者的治疗,其预后风险不同,治疗策略不同。本文主要概述了目前MDS的治疗方法。The heterogeneous nature of myelodysplastic syndrome(MDS)demands a complex and personalized variety of therapeutic approaches.As yet,allogeneic hematopoietic stem cell transplantation remains the only potentially curative option.However,it is not accessible to a number of patients for various reasons.For the majority of patients with MDS,treatment strategies are risk adapted mainly based on the revised version of the International Prognostic Scoring System(IPSS-R).This review provides an overview of the current therapeutic landscape in MDS.

关 键 词：骨髓增生异常综合征 治疗 研究现状 

分 类 号：R551.3[医药卫生—血液循环系统疾病]